Open AccessCost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Author(s) -
Longfeng Zhang,
Na Li,
Maobai Liu,
Bin Zheng,
Zhijuan Wu,
Hongfu Cai
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s293983
Subject(s) - gefitinib , medicine , lung cancer , oncology , cost effectiveness analysis , clinical trial , cost effectiveness , epidermal growth factor receptor , cancer , risk analysis (engineering)
The objective of the study was to evaluate the economics of dacomitinib and gefitinib in the first-line treatments for EGFR-positive advanced or metastatic non-small cell lung cancer (NSCLC) from a US payer perspective.